Thalidomide affects the skeletal system of young rats

Area of Science:

• Pharmacology
• Orthopedics
• Toxicology

Background:

• Thalidomide is used for immune-related, neoplastic, and inflammatory diseases.
• Its effects on the skeletal system, particularly in young individuals, are not well-understood.

Purpose of the Study:

• To investigate the impact of thalidomide on bone tissue in young rats.
• To determine dose- and time-dependent effects on skeletal parameters.

Main Methods:

• 5-week-old male Wistar rats were administered thalidomide (15, 30, or 60 mg/kg) for 1, 3, or 6 weeks.
• Evaluated body mass gain, bone mass (tibia, femur, L-4 vertebra), and histomorphometric parameters.

Main Results:

• No significant effects were observed after 1 or 3 weeks of thalidomide administration.
• After 6 weeks, significant bone remodeling disturbances were noted, increasing with dose.
• High doses (60 mg/kg) reduced bone mass, inhibited bone formation, and increased resorption.

Conclusions:

• Thalidomide's skeletal effects in young rats are dose- and time-dependent.
• Prolonged exposure (6 weeks) at higher doses significantly disrupts bone remodeling.
• Thalidomide inhibits bone formation and enhances bone resorption in juvenile rats.